Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib in Myelodysplastic Syndrome (MDS)
NCT00072475Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2003
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatalanib in myelodysplastic syndrome (MDS), sponsored by Cancer and Leukemia Group B. Primary endpoints: Response Rate (Hematologic Improvement, Complete/Partial Remission) up to 5 years and Time to Transformation to Acute Myeloid Leukemia or Death up to 5 years. Started Dec 2003; status: completed.
02
Drugs
vatalanib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00072475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072475.